Alexza with Bio*One Capital shall initiate commercial manufacturing in Singapore. A key element of Alexza's commercial manufacturing strategy is the development of production for the Staccato device-related plastic and electronics components of our commercial product single-dose device.

Alexza Pharmaceuticals announced that Bio*One Capital Pte. Ltd, one of the largest dedicated biomedical investment management companies in Asia, has committed to purchase $10 million of common stock in Alexza.  The investment by Bio*One is being made in conjunction with Alexza's formation of Alexza Singapore Pte. Ltd., a wholly owned subsidiary.  Alexza intends to initiate manufacturing operations for key components of Alexza's single-dose Staccato® device in Singapore.  Alexza's single-dose Staccato devices are used in a majority of its current product candidates, including its lead program, AZ-004 (Staccato loxapine), which is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients.

Related Items:

---

Be first to comment this article

Only registered users can write comments.
Please login or register.